Afficher la notice abrégée

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles

hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorRODALLEC, Anne
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorSICARD, Guillaume
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorFANCIULLINO, Raphaelle
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
dc.contributor.authorBENZEKRY, Sébastien
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorLACARELLE, Bruno
hal.structure.identifierCentre de Lutte contre le Cancer Antoine Lacassagne [Nice] [UNICANCER/CAL]
dc.contributor.authorMILANO, Gérard
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorCICCOLINI, Joseph
dc.date.accessioned2024-04-04T03:03:00Z
dc.date.available2024-04-04T03:03:00Z
dc.date.issued2018-10-24
dc.identifier.issn1742-5255
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/193036
dc.description.abstractEnImmune checkpoint inhibitors have considerably changed the landscape of oncology. However apart from world-acclaimed success stories limited to melanoma and lung cancer, many solid tumors failed to respond to immune checkpoint inhibitors due to limited immunogenicity, unfavorable tumor micro-environments (TME), lack of infiltrating T lymphocytes or increases in Tregs. Areas covered: Combinatorial strategies are foreseen as the future of immunotherapy and using cytotoxics or modulating agents is expected to boost the efficacy of immune checkpoint inhibitors. In this respect, nanoparticles displaying unique pharmacokinetic features such as tumor targeting properties, optimal payload delivery and long-lasting interferences with TME, are promising candidates for such combinations. This review covers the basis, expectancies, limits and pitfalls of future combination between nanoparticles and immune check point inhibitors. Expert opinion: Nanoparticles allow optimal delivery of variety of payloads in tumors while sparing healthy tissue, thus triggering immunogenic cell death. Depleting tumor stroma could further help immune cells and monoclonal antibodies to better circulate in the TME, plus immune-modulating properties of the charged cytotoxics. Finally, nanoparticles themselves present immunogenicity and antigenicity likely to boost immune response at the tumor level.
dc.language.isoen
dc.publisherTaylor & Francis
dc.subject.enImmunotherapy
dc.subject.ennanoparticles
dc.subject.enimmunogenicity
dc.subject.endrug delivery
dc.subject.enpharmacokinetics
dc.subject.encancer
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents, Immunological
dc.subject.meshDrug Delivery Systems
dc.subject.meshHumans
dc.subject.meshImmunotherapy
dc.subject.meshNanoparticles
dc.subject.meshNeoplasms
dc.subject.meshT-Lymphocytes
dc.subject.meshT-Lymphocytes, Regulatory
dc.subject.meshTumor Microenvironment
dc.title.enTurning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles
dc.typeArticle de revue
dc.identifier.doi10.1080/17425255.2018.1540588
dc.subject.halSciences du Vivant [q-bio]/Cancer
dc.subject.halInformatique [cs]/Modélisation et simulation
dc.subject.halSciences du Vivant [q-bio]
bordeaux.journalExpert Opinion on Drug Metabolism and Toxicology
bordeaux.page1-9
bordeaux.volume14
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.issue11
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.peerReviewedoui
hal.identifierhal-01958583
hal.version1
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-01958583v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Expert%20Opinion%20on%20Drug%20Metabolism%20and%20Toxicology&rft.date=2018-10-24&rft.volume=14&rft.issue=11&rft.spage=1-9&rft.epage=1-9&rft.eissn=1742-5255&rft.issn=1742-5255&rft.au=RODALLEC,%20Anne&SICARD,%20Guillaume&FANCIULLINO,%20Raphaelle&BENZEKRY,%20S%C3%A9bastien&LACARELLE,%20Bruno&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée